Biotechnology

Bridgebio Pharma

BridgeBio Pharma Executive Trimarchi Sells 13,651 Shares for $2.41 Million

BridgeBio Pharma Director Randal W. Scott Sells Approximately $656K in Stock

BridgeBio Pharma Partners with BlackDoctor and HealthyWomen to Raise Awareness of ATTR-CM

BridgeBio Releases Phase 3 Trial Results for Encaleret in Autosomal Dominant Hypocalcemia Type 1

BridgeBio evaluates acoramidis impact on NT-proBNP levels

BridgeBio Pharma Announces Acoramidis Phase III Trial Significantly Reduces Outpatient Heart Failure Events

Bridgebio Pharma released FY2026 Q1 earnings on May 7 After-Market (EST), actual revenue USD 194.52 M (forecast USD 178.61 M), actual EPS USD -0.8421 (forecast USD -0.6788)

BridgeBio Pharma Outlines Rare Disease Pipeline and Business Strategy

BridgeBio Pharma to present encaleret Phase 3 CALIBRATE results at the European Congress of Endocrinology

Bridgebio Pharma to release FY2026 Q1 earnings on May 7 After-Market EST, forecast revenue USD 178.61 M, EPS USD -0.6788

BridgeBio Oncology Therapeutics Unveils Preclinical Data for BBO-10203

Assenagon Asset Management S.A. Significantly Reduces Holdings in BridgeBio Pharma

BridgeBio Reveals Long-Term Data on Acoramidis for Cardiomyopathy

BridgeBio Submits NDA for Limb-Girdle Muscular Dystrophy 2I/R9 Drug BBP-418

BridgeBio to Present Acoramidis Phase 3 Trial Data at Annual Scientific Meeting

BridgeBio Reports Mid-Term Results of Phase III FORTIFY Trial for BBP-418 in Limb-Girdle Muscular Dystrophy 2I/R9

BridgeBio Pharma Director Andrea Ellis Sells Company Shares

Positive Third-Stage FORTIFY Results of BBP-418 Alter BridgeBio Pharma's Investment Story

BridgeBio Pharma CEO Discusses Clinical Progress and Future Plans at Medical Conference

BridgeBio Pharma to Present Mid-Stage Trial Data on BBP-418 at MDA Conference

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

BBIO

LABU

ARKG

SBIO

BridgeBio Pharma received a Hold rating and price target from Citi analyst today.Claim 55% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks In addition to Citi, BridgeBio Pharma also received a Hold from J.P. Morgan’s Eric Joseph in a report issued today. However, on May 13, Bank of America Securities reiterated a Buy rating on BridgeBio Pharma (NASDAQ: BBIO).

Tip Ranks

iShares Global Healthcare

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

Ark Genomic Revolution ETF

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

VG Health

Proshares Ultra Nasdaq Biotech

Direxion S&P Biotech Bear 3X

iShares Biotechnology ETF

ALPS Medical Breakthrough

Health Care Select Sector SPDR

Citigroup

JPMorgan Chase

Bank of America

CITIGROUP INC 6.250 NON CUM SER II PFD WI

JPMORGAN CHASE & CO. 4.20% DEP SHS REPSTG 1/400TH PFD SER MM

JPMORGAN CHASE & CO. 6%NON CUM DEP SHS REP 1/400TH PFD SER EE

JPMORGAN CHASE & CO. DEP REP 1/400TH (5.75% NON CUM PFD DD)

JPMORGAN CHASE & CO. 4.625% DEP SH RE 1/400TH INT NO CU PF LL

JPMorgan Chase & Co.

JPMORGAN CHASE & CO. 4.55% DEP SHS REPSTG 1/400TH PFD SER JJ

JPMORGAN CHASE & CO. 4.75 DEP SHS REP 1/400 NCUM PFD SR GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

BridgeBio Pharma (BBIO) Gets a Hold from Citi

VIRGINIA RETIREMENT SYSTEMS ET Al increased its stake in BridgeBio Pharma, Inc. by 146.2% in Q4, owning 25,850 shares valued at $1,977,000. Other institutional investors also raised their holdings. Analysts have a consensus 'Moderate Buy' rating for the stock, with a target price of $88.19. BridgeBio reported a revenue of $194.52 million but missed EPS estimates. Insider selling included 10,000 shares by Director Randal W. Scott and 40,000 shares by CEO Neil Kumar.

Market Beat

First Horizon

Huntington Bancshares

Truist Financial

ROYAL BANK OF CANADA

Wells Fargo

FIRST HORIZON CORPORATION 6.50% DEP SHS REP 1/4000 PER PFD SER E

FIRST HORIZON CORPORATION DEP SHS REP 1/400 NON CUM PER PFD SER C

FIRST HORIZON CORPORATION DEP SHS REP 1/400 NON CUM PER PFD SER B

FIRST HORIZON CORPORATION DEP SH REP 1/4000 INT NON CUM PFD H WI

FIRST HORIZON CORPORATION DEP SHS REPSTG 1/4000TH PERP PFD SER F

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

VIRGINIA RETIREMENT SYSTEMS ET Al Increases Stock Holdings in BridgeBio Pharma, Inc. $BBIO

BridgeBio Pharma is collaborating with BlackDoctor and HealthyWomen to raise awareness about ATTR-cardiac amyloidosis (ATTR-CM), a heart condition often overlooked in women. A recent survey revealed that 73% of respondents had never heard of ATTR-CM, with 95% never screened for it. The company aims to improve diagnosis and treatment access for women, particularly in the Black community, where 1 in 25 carries a genetic variant linked to the disease. BridgeBio's treatment, Attruby, generated $146 million in sales in Q4 2024.

Fiercepharma

Pfizer

BridgeBio helps spotlight ATTR-CM's hidden impact on women

BridgeBio Pharma executives expressed confidence in the commercial trajectory of their product Attruby during a BofA healthcare conference. They anticipate three potential product launches from their late-stage pipeline, projecting Attruby could achieve peak U.S. sales of around $4 billion. The company also highlighted its focus on positioning Attruby as a first-line treatment and discussed ongoing research to differentiate it from competitors. Additionally, BridgeBio expects to launch BBP-418, encaleret, and infigratinib in the coming months, with a combined peak-year sales potential exceeding $8 billion.

BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches

The primary findings of Phase 3 CALIBRATE were recently revealed during a presentation at the 2026 ECE. The results showcased the fast and long-lasting advantages of encaleret in ADH1, including significant improvements across crucial clinical measures.

Unusual Whales

BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

Pharmaceutical Technology

Invesco Nasdaq Biotechnology ETF

BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial

Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure | BBIO Stock News

StockTitan

Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure | BBIO Stock News

Bridgebio Pharma(BBIO.US)

BridgeBio Pharma (BBIO) Gets a Hold from Citi

VIRGINIA RETIREMENT SYSTEMS ET Al Increases Stock Holdings in BridgeBio Pharma, Inc. $BBIO

BridgeBio helps spotlight ATTR-CM's hidden impact on women

BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches

BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1

BridgeBio’s Attruby challenges Pfizer’s Vyndamax legacy in pivotal ATTR trial

Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure | BBIO Stock News